Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of Oncolytic Virus (OH2) Intratumoral Injection in Locally Advanced or Metastatic Bladder Cancer a Phase Ⅱ Clinical Trial

NCT05248789 is registered in ClinicalTrials.gov with Binhui Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05248789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05248789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of Oncolytic Virus (OH2) Intratumoral Injection in Locally Advanced or Metastatic Bladder Cancer a Phase Ⅱ Clinical Trial
Lead sponsor
Binhui Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
May 25, 2022
Completion date
October 28, 2024
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced bladder carcinoma